SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Exclusion Criteria

• •Participants who have vascular malformations that interfere with evaluating the target microcystic lymphatic malformation
• •Participants with complicated vascular anomalies with severe systemic symptoms that require systemic therapy
• •The participant's treatment area is mainly in any wet mucosa or within the orbital rim
• •Participants who are pregnant or planning to become pregnant